Why Affimed N.V. Stock Is Soaring Today
Shares of Affimed N.V. (NASDAQ: AFMD) are rising sharply on Wednesday following the company's release of a clinical update regarding one of its pipeline candidates. As of 1:40 p.m. EST, Affimed's stock was up by 15.2% after rising by as much as 20.7% earlier in the day.
Affimed NV is investigating AFM13 as a treatment for relapsed or refractory CD30-positive peripheral T-cell lymphoma (PTCL). Today, the company announced that it would continue enrolling patients for a phase 2 clinical trial for AFM13 after a preplanned interim futility analysis demonstrated positive results.
The analysis showed that the response rate in cohort A in the trial achieved a predefined threshold for the continuation of the study. Meanwhile, the response rate in cohort B was comparable enough to that of cohort A to justify combining both into a single cohort.
Source Fool.com
